Pure Global

Study of 5% VVN001 Ophthalmic Solution in Dry Eye Disease - Trial NCT06360133

Access comprehensive clinical trial information for NCT06360133 through Pure Global AI's free database. This Phase 3 trial is sponsored by VivaVision Biotech, Inc and is currently Not yet recruiting. The study focuses on Dry Eye. Target enrollment is 700 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT06360133
Phase 3
Not yet recruiting
drug
Trial Details
ClinicalTrials.gov • NCT06360133
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
Study of 5% VVN001 Ophthalmic Solution in Dry Eye Disease
A Phase 3, Randomized, Double-Masked, Vehicle-controlled, Multi-center Study Evaluating the Safety and Efficacy of 5% VVN001 in Chinese Subjects With Dry Eye Disease

Study Focus

Dry Eye

VVN001 Ophthalmic Solution, 5%

Interventional

drug

Sponsor & Location

VivaVision Biotech, Inc

Shanghai, China

Timeline & Enrollment

Phase 3

Apr 01, 2024

Mar 01, 2026

700 participants

Primary Outcome

Corneal Fluorescein Staining

Summary

This is a Phase 3, randomized, double-Masked, vehicle-controlled, multi-center study designed
 to evaluate the safety and efficacy of 5% VVN001 Ophthalmic Solution versus vehicle in
 Chinese subjects with dry eye disease.

ICD-10 Classifications

Ocular pain
Avulsion of eye
Other corneal deformities
Corneal ulcer
Dry mouth, unspecified

Data Source

ClinicalTrials.gov

NCT06360133

Non-Device Trial